BioSpace News Archive

Drug Development

COVID-19: New Subvariant Gains Traction and Hopeful News for the Immunocompromised

As the world speculates the potential impact of the novel COVID-19 variant omicron XE and subvariant BA.2, research continues to shed light on the impact and future of the pandemic.

April 13, 2022
·
3 min read
·
Jazmine Colatriano, M.S.
Drug Development

AACR Spotlight: Victoria’s Secret Awards 5 Female Cancer Researchers, AbbVie and More

As the American Association of Cancer Research (AACR) Annual Meeting wraps up, there were some surprising and exciting research news and presentations.

April 13, 2022
·
4 min read
·
Mark Terry
Drug Development

ProQR to Cut 30% of Workforce, CSO Following Unexpected Trial Failure

ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.

April 13, 2022
·
2 min read
·
Hannah Chudleigh
BioCapital

Gain’s Parkinson’s Asset Generates Excitement in Early Research

Gain Therapeutics’ candidate compound for Parkinson’s Disease demonstrated the ability to increase GCase protein levels and enhance neuronal activity.

April 13, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

9 Meters Scores Patent for Hyperphagia, Obesity-Fighting Drug

9 Meters Biopharma has received notice from the U.S. Patent and Trademark Office (USPTO) allowing its patent for therapeutic NM-136 to treat hyperphagia (extreme hunger) and obesity.

April 13, 2022
·
3 min read
·
Hayley Shasteen
Business

Money on the Move: April 6-13

Companies working on cell therapies got most of the funding in the life sciences venture capital world this week. For that and more, continue reading.

April 13, 2022
·
3 min read
·
Hannah Chudleigh
Business

IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments

IN8bio, Inc. announced the additions to its clinical and regulatory team as the Company seeks to expand its clinical pipeline with at least one new company sponsored investigational new drug application this year.

April 13, 2022
·
5 min read
Drug Development

Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma

Oncternal Therapeutics, Inc. today announced that it has deprioritized further development of ONCT-216 to reallocate resources to zilovertamab.

April 13, 2022
·
8 min read
BioMidwest

Gift of Life Biologics Closes Seed $6m Funding Round, Illustrating Investor Confidence in Future Demand for Cell & Gene Therapy Starting Material

Gift of Life Biologics Inc., a vertically integrated supplier of allogeneic cellular starting material to the biopharmaceutical industry, announces the close of its $6m seed financing round.

April 13, 2022
·
2 min read
Business

Apollo Endosurgery to Report First Quarter Results on May 3, 2022

Apollo Endosurgery, Inc. announced that the Company is scheduled to release financial results for the first quarter ended March 31, 2022 on Tuesday, May 3, 2022, after market close.

April 13, 2022
·
2 min read